Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Status:
Completed
Trial end date:
2019-01-29
Target enrollment:
Participant gender:
Summary
This international, multi-center, open-label, single-arm study evaluated the safety and
tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative
locally advanced or metastatic breast cancer after documented recurrence or progression
following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent
growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to
confirm no difference in safety and efficacy. Summary statistics were presented.